fluorescein-thiourea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: fluorescein-thiourea
• 英文别名: 3',6'-Dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one;thiourea；3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one;thiourea
• 化学式: CH₄N₂S*C₂₀H₁₂O₅
• 分子量: 408.434
• InChiKey: BDMQMNYITIESGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.85
• 重原子数：
  29
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  160
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  硫脲 、 荧光素 以 aq. phosphate buffer 为溶剂， 生成 fluorescein-thiourea
  参考文献：
  名称：

  使用荧光素/硫脲传感器作为水介质中的受体比色检测 Hg2+ 离子

  摘要：

  使用一种简单且选择性的比色法检测水性介质和环境水样中的汞离子 (Hg 2+ )。作为受体的荧光素-硫脲 ( FLTU ) 偶联物​​复合物由 10μmol L -1荧光素染料和硫脲在 pH 7.00 的磷酸盐缓冲溶液中以1:1 的摩尔比制备。FLTU 受体的红外光谱表明硫脲和荧光素染料之间形成了 H 键。受体荧光素硫脲 ( FLTU ) 被用作高度选择性地检测 Hg 2+的化学传感器通过受体荧光强度的淬灭，将受体颜色从黄色变为红色。通过吸收光谱法测定的 Hg 2+离子与受体FLTU 的检测下限 (LOD) 和定量限 (LOQ)分别为 0.24 和 0.73 nmol L –1（相关系数 R 2 = 0.985）。汞离子很有前景，可以通过以 1:1 的受体与 Hg 2+离子的化学计量比形成复合物来实现。

  DOI：

  10.1016/j.jphotochem.2021.113569

文献信息

• [EN] ANTI-CANCER COMPOUNDS AND METHODS RELATED THERETO<br/>[FR] COMPOSES ANTICANCEREUX ET PROCEDES S'Y RAPPORTANT
  申请人：STEWART JOHN M

  公开号：WO2000011022A1

  公开（公告）日：2000-03-02

  The present invention provides compounds useful to inhibit tumor growth and to induce apoptosis. In general, the anti-cancer agents (ACA) are described by the formula (I): [ACA]n-X wherein, X is a linker group having 2-5 functional groups or is absent, n = 1, and ACA is selected from the group consisting of Formula (II), Formula (III), Formula (IV), Formula (V), and Formula (VI), as described herein. Other compounds described herein are defined by the Formula (VII), as described herein.

  本发明提供了一种有用的化合物，可用于抑制肿瘤生长和诱导细胞凋亡。一般来说，抗癌药物（ACA）由公式（I）描述：[ACA]n-X其中，X是具有2-5个功能基团的连接基团或不存在，n = 1，而ACA选自本文所述的公式（II），公式（III），公式（IV），公式（V）和公式（VI）的群组。本文还描述了其他化合物，其由公式（VII）所定义，如本文所述。
• CYCLOPEPTIDE DERIVATIVES
  申请人：——

  公开号：US20020032306A1

  公开（公告）日：2002-03-14

  The invention relates to compounds of the formula (I) R1 Q1 XQ2 R2, in which: Q1, Q2, each independent of one another, are missing or are NH(CH2)n CO; R1, R2, each independent of one another, are missing or are cyclo(ArgGlyAspZ), wherein Z is missing in the side chain of Q1 or Q2 or if Q1 and/or Q2 are missing, is bound to X, at least one of the groups R1 or R2 always having to be included; X is COR 18 CO, and if R1 Q1 or R2 Q2 are missing is R10, R13, R16, HetCO or a fluorescent pigment residue linked through a CONH, COO, NHC (═S)NH, NHC(═O)NH, SO2 NH or NHCO bond; and Z, R10, R13, R16, R18, Het and n have the meanings given in claim 1. The invention also relates to the salts of said compounds. Said compounds and their salts can be used as integrin inhibitors, in particular for the prevention and treatment of circulatory diseases, thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, angiogenic diseases and in tumor therapy.

  本发明涉及式(I)的化合物，其中：Q1，Q2，互相独立，可以缺失或为NH(CH2)n CO; R1，R2，互相独立，可以缺失或为环状(ArgGlyAspZ)，其中Z在Q1或Q2的侧链中缺失或如果Q1和/或Q2缺失，则与X结合，其中必须始终包括R1或R2中的至少一个基团; X为COR 18 CO，如果R1 Q1或R2 Q2缺失，则为R10，R13，R16，HetCO或通过CONH、COO、NHC(═S)NH、NHC(═O)NH、SO2 NH或NHCO键连接的荧光色素残基; Z，R10，R13，R16，R18，Het和n的含义如权利要求书中所述。本发明还涉及所述化合物的盐。所述化合物及其盐可用作整合素抑制剂，特别用于预防和治疗循环疾病、血栓、心肌梗塞、冠心病、动脉硬化、血管生成性疾病和肿瘤治疗。
• METHOD FOR MONITORING, DIAGNOSING, AND SCREENING CANCER THROUGH MEASURING THE CONCENTRATION OF DES-R PROTHROMBIN ACTIVATION PEPTIDE FRAGMENT F2 (DES-R F2) IN A SERUM
  申请人：Bioinfra Inc.

  公开号：EP2251354A1

  公开（公告）日：2010-11-17

  The present invention relates to a method for diagnosing and screening cancer through measuring the concentration of des-R prothrombin activation peptide fragment F2 (des-R F2) in a serum. More specifically, des-R-prothrombin activation peptide fragment F2 which is the protein marker down-regulated specifically in liver cancer, breast cancer, and stomach cancer, and a method for diagnosis and screening of liver cancer, breast cancer, and stomach cancer by quantifying the protein marker. The protein marker of the present invention can be effectively used for diagnosis and screening of liver cancer, breast cancer and stomach cancer by comparing the expression of the said protein marker in a normal subject with that of a liver cancer, breast cancer, or stomach cancer patients.

  本发明涉及一种通过测量血清中 des-R 凝血酶原活化肽片段 F2（des-R F2）的浓度来诊断和筛查癌症的方法。更具体地说，des-R-凝血酶原活化肽片段 F2 是肝癌、乳腺癌和胃癌中特异性下调的蛋白质标记物，本发明还涉及一种通过量化该蛋白质标记物来诊断和筛查肝癌、乳腺癌和胃癌的方法。通过比较上述蛋白标记物在正常人和肝癌、乳腺癌或胃癌患者中的表达情况，本发明的蛋白标记物可以有效地用于肝癌、乳腺癌和胃癌的诊断和筛查。
• METHOD FOR NONINVASIVE PREDICTION OR DIAGNOSIS OF INFLAMMATION AND INFECTION IN AMNIOTIC FLUID OF PATIENTS WITH PREMATURE RUPTURE OF MEMBRANES
  申请人：SNU R & DB Foundation

  公开号：EP3396382A2

  公开（公告）日：2018-10-31

  The present invention relates to a method for noninvasive prediction or diagnosis of inflammation and/or infection in amniotic fluid leaked through the cervix into the vagina to predict the concentration of inflammatory markers in the amniotic fluid inside uterus by measuring the concentration of inflammatory markers (various cytokines). More particularly, the present invention relates to a method for prediction or diagnosis of inflammation and/or infection in amniotic fluid by measuring the concentration of markers (IL-6, IL-1β IL-8, MCP-1, GRO-α) in the amniotic fluid leaked through the cervix into the vagina in patients with premature rupture of membranes. The method of the present invention can be performed more stably on pregnant women, as compared to the conventional method for prediction or diagnosis of inflammation and/or infection using invasively collected amniotic fluid.

  本发明涉及一种无创预测或诊断经子宫颈漏入阴道的羊水中的炎症和/或感染的方法，通过测量炎症标志物（各种细胞因子）的浓度来预测子宫内羊水中炎症标志物的浓度。更具体地说，本发明涉及一种通过测量胎膜早破患者经宫颈漏入阴道的羊水中的标记物（IL-6、IL-1β IL-8、MCP-1、GRO-α）浓度来预测或诊断羊水中的炎症和/或感染的方法。与使用侵入性收集羊水预测或诊断炎症和/或感染的传统方法相比，本发明的方法可在孕妇身上更稳定地实施。
• Method for using information on complex biomarker group to diagnose lung cancer in a subject and diagnostic kit and computing system using the same
  申请人：BioInfra Inc.

  公开号：US10663469B2

  公开（公告）日：2020-05-26

  A method for diagnosing lung cancer in a subject by using a complex biomarker group is provided. The method includes steps of: (a) a computing system (1) acquiring a model M by using expression level data by individual biomarkers in the complex biomarker group and then (2) acquiring expression level data by the individual biomarkers measured from a biological specimen of the subject or their processed data Bk; and (b) the computing system determining whether lung cancer is detected in the subject by using the acquired data of the subject by referring to the model M; wherein the complex biomarker group includes CEA, HE4, ApoA2, TTR, sVCAM-1 and RANTES.

  本研究提供了一种利用复杂生物标志物组诊断受试者肺癌的方法。该方法包括以下步骤(a) 计算系统(1)通过使用复杂生物标志物组中单个生物标志物的表达水平数据获取模型M，然后(2)获取从受试者的生物标本或其处理数据Bk测量的单个生物标志物的表达水平数据；以及(b)计算系统通过使用所获取的受试者数据参照模型M确定是否在受试者中检测到肺癌；其中复杂生物标志物组包括CEA、HE4、ApoA2、TTR、sVCAM-1和RANTES。